Health Care·Pharmaceuticals·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.38 | N/A | +10.14% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.38 | N/A | +10.14% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management acknowledged the impact of external factors on performance. They expressed a focus on navigating the current environment.
Management noted the challenges posed by the current market conditions.
They emphasized their commitment to maintaining operational efficiency.
Phibro Animal Health reported a better-than-expected EPS for the quarter, but the stock fell nearly 4% in reaction. Investors may be concerned about the lack of revenue figures and guidance, which could indicate uncertainty about future performance. The market's response suggests that while the EPS beat is positive, it was not enough to offset broader concerns.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SEMPRA
May 4, 2020